Everest Medicines’ Licensing Partner Venatorx Pharmaceuticals Announces Publication of Positive Results from Cefepime-Taniborbactam’s Phase 3 CERTAIN-1 Study in New England Journal of Medicine

–Cefepime-taniborbactam was superior to meropenem for the composite efficacy endpoint with composite efficacy sustained at late follow-up visit– SHANGHAI, Feb. 20, 2024 /PRNewswire/ — Everest Medicines (HKEX 1952.HK)’s licensing partner, Venatorx Pharmaceuticals announced that The New…